The biotech companies Roche and Zealand Pharma have concluded a collaboration and licensing agreement to develop and commercialise the weight loss drug petrelintide and future potential combination products with petrelintide, including a combination of petrelintide and Roche’s weight loss drug candidate CT-388.
As part of the agreement, Zealand Pharma will receive an upfront payment of USD 1.65 billion, while the total agreement is worth up to USD 5.3 billion through potential milestone payments. In return, Zealand Pharma will pay Roche USD 350 million for making CT-388 available as a combination therapy.
Profits or losses from petrelintide sales will be split equally between the two companies in the USA and Europe, while Zealand Pharma will receive royalties from sales in the rest of the world.
Accura advised Roche in connection with all Danish capital market aspects of the matter.